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Francisco Abad-Santos1,2,4,*
In December 2019, the severe acute respiratory syndrome virus-2 pandemic began, causing the coronavirus disease 2019. A 
vast variety of drugs is being used off-label as potential therapies. Many of the repurposed drugs have clinical pharmacoge-
netic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this 
review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to 
prescribe them more safely.
In December 2019, the pandemic of the severe acute respi-
ratory syndrome virus-2 (SARS-CoV-2) started in Wuhan, 
China. This virus causes the novel coronavirus disease 
2019 (COVID-19). By the end of May 2020, more than 
5  million cases and 330,000 deaths were declared.1 The 
management of the disease includes preventive and thera-
peutic strategies and the treatment of the acute respiratory 
distress syndrome and the cytokine storm.2 A vast variety 
of drugs are being used as off-label therapies.3,4 Until the 
effectiveness of any of these repurposed drugs against the 
SARS-CoV-2 virus is demonstrated in randomized clinical 
trials, their off-label use will likely continue. The first out-
break of the pandemic ended in June 2020 in Europe, as 
the pandemic slowed down in the summer. However, in the 
American continent, the pandemic is currently in an acceler-
ated phase. In addition, the risk for outbreaks and a second 
wave in autumn exists, both in Europe and worldwide.
Due to the novelty of the disease, physicians may not be 
aware of the usefulness of pharmacogenetic biomarkers. This 
applies especially to those clinicians whose medical special-
ties are not related to infectious or respiratory diseases but 
had to treat patients with COVID-19 due to the health crisis. 
Many of the investigational repurposed drugs have clinical 
pharmacogenetic guidelines available with therapeutic rec-
ommendations when prescribed as indicated on the drug 
label. In addition to pharmacogenetic biomarkers, it is of 
great importance to assess drug interactions. Researchers 
in the University of Liverpool developed an online tool, which 
includes many (but not all) of the repurposed drugs used 
in clinical practice for the detection of these interactions.5 
As an example of the usefulness of pharmacogenetic infor-
mation, two of the prescribed agents are chloroquine and 
hydroxychloroquine. They are originally indicated for ma-
laria and autoimmune diseases6 and were related to severe 
hemolysis crisis in a patient with deficient glucose-6-phos-
phate dehydrogenase (G6PD).7 Although other authors 
published opposing results,8 for primaquine, which belongs 
to the same family of antimalarial drugs, this association is 
well-demonstrated.9 As an alternative to enzymatic assays, 
this deficit can be determined with pharmacogenetic bio-
markers, as it will be further explained below. Hence, the 
purpose of this review is not to confirm or deny the effective-
ness of drugs used for COVID-19. Alternatively, we aimed to 
provide a summary of pharmacogenetic biomarkers avail-
able for these drugs, which may help prescribe them more 
safely. In this review, two criteria were used to include drugs: 
(1) drugs frequently used to treat COVID-19 and for which 
any useful pharmacogenetic information is available10 or (2) 
drugs barely used to treat COVID-19 but with relevant phar-
macogenetic information available.
Once the review was finished, we classified the biomark-
ers into four evidence levels: (1) level 1 evidence involves 
pharmacogenetic biomarkers with clinical pharmacogenetic 
guidelines (i.e., those drugs where a particular genotype 
is related to the efficacy or safety of the drug and where 
therapy must be adjusted according to the genotype. These 
biomarkers were extensively studied for years and are al-
ready validated in clinical practice; a pharmacogenetic test 
prior to drug prescription is warranted. (2) Level 2 evidence 
applies to drugs associated with an adverse drug reaction 
and a specific pharmacogenetic biomarker, which do not yet 
have a specific guideline. The evidence for this association is 
very high and was validated with other drugs. For instance, 
hydroxychloroquine/chloroquine. G6PD deficiency was re-
ported to be related to the risk of acute hemolytic anemia in 
patients receiving rasburicase. There is a pharmacogenetic 
guideline for rasburicase, but not yet for hydroxychloroquine/
chloroquine, even though the risk of hemolysis in patients 
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with G6PD deficiency receiving these drugs was reported. 
A pharmacogenetic test prior to drug prescription is war-
ranted. (3) Level 3 evidence involves drugs without sufficient 
pharmacogenetic information but related to pharmacogenes 
(i.e., genes related to metabolism or mechanism of action). 
In addition, the Pharmacogenomics Knowledgebase in-
cludes clinical annotations for these associations, however, 
no pharmacogenetic recommendations are indicated. These 
were considered “candidate pharmacogenetic biomarkers” 
as they need to be validated in clinical practice. Currently, a 
pharmacogenetic test prior to drug prescription cannot be 
warranted. (4) Level 4 evidence groups drugs with no or al-
most no pharmacogenetic information available (i.e., without 
any Pharmacogenomics Knowledgebase clinical annota-
tion). However, they are related to pharmacogenes, so they 
were considered “speculative biomarkers.” In summary, 
levels 1 and 2 group together drugs in which a pharmacog-
enetic test is warranted and levels 3 and 4 are drugs where, 
to date, there is insufficient evidence to recommend a phar-
macogenetic test (Figure 1).
Table 1 depicts a summary of the drugs included in this 
review, along with the respective pharmacogenetic bio-
marker and the level of evidence of each association.
CHLOROQUINE AND HYDROXYCHLOROQUINE
Chloroquine and hydroxychloroquine were among the 
most utilized repurposed therapeutic agents during the 
first stages of the pandemic. These drugs demonstrated in 
vitro activity against SARS-CoV-2 virus for what they were 
vastly used off-label for the management of COVID-19. The 
Centers for Disease Control and Prevention (CDC) guide-
line “Information for Clinicians on Therapeutic Options for 
COVID-19 Patients” included chloroquine as an optional 
treatment,11 however, its clinical effectiveness was ques-
tioned.12,13 In addition, a recent study reported an increased 
death rate in patients treated with these drugs.14 On June 
15, 2020, the US Food and Drug Administration (FDA) re-
voked the Emergency Use Authorization for chloroquine 
and hydroxychloroquine, due to serious cardiac adverse 
events reported. The FDA considered that the potential 
benefits of the use of chloroquine and hydroxychloroquine 
no longer outweigh the actual potential risks.15 However, the 
prophylactic use of chloroquine and hydroxychloroquine in 
clinical trials continues.16 The decision against using these 
drugs for the treatment of COVID-19 is not applicable to 
their pre-exposure and post-exposure use.17
Because chloroquine and hydroxychloroquine may still be 
used, we depict here all the available pharmacogenetic in-
formation. To date, their mechanism of action is not perfectly 
known, and different theories still emerge. Both compounds 
are weak bases with a half-life of around 50 days. They inhibit 
cytokine synthesis by interacting with transcriptional activity; 
they modulate the release of stimulant molecules, altering 
lysosomal activity, signaling pathways and autophagy.18
Although no pharmacogenetic testing is recommended 
before starting treatment with chloroquine and hydroxy-
chloroquine, the FDA and Swiss drug labels state that they 
may cause hemolysis in patients who are G6PD deficient. 
This could be especially important when chloroquine and 
hydroxychloroquine are co-administered with other hemoly-
sis-inducing drugs, such as penicillin, methyldopa, and some 
cephalosporins.19–22 CDC guidelines recommend a reduced 
dose of 300  mg (half of the standard dose of 600  mg) of 
chloroquine to those with G6PD deficiency. This dose adjust-
ment can be considered as an indirect recommendation for 
genetic testing.23 Although, to date, no specific G6PD defi-
ciency testing is recommended,11 such deficiency can easily 
Figure 1 Levels of evidence for the pharmacogenetic testing and application of clinical recommendations for drugs used in the 
treatment of coronavirus disease 2019 and percentage of drugs per evidence level.
Level of evidence Pharmacogenetic recommendation
No evidence to warrant
a pharmacogenetic test
Not enough evidence to 
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be identified by genotyping the gene. The most common 
deficiency haplotype is often referred to as G6PD A- and com-
posed of rs1050828 (c.202C > T) and rs1050829 (c.376T > C) 
variants. These two polymorphisms have an average minor 
allele frequency (MAF) of 15% and 39%, respectively, in 
African populations. The cause of their high prevalence in 
Africa is due to its protective effect against malaria infection. 
The most common white race variant is rs1050829 with 0.4% 
MAF, and with 0.6% MAF in the Mediterranean population.24 
A higher risk of chloroquine and hydroxychloroquine toxicity 
may be linked to these genotypes/haplotypes; therefore, 
physicians should avoid prescribing these drugs to carriers 
of mutant alleles. In addition, cytochrome P450 (CYP) 2C8, 
CYP3A4, and CYP2D6 are the main CYP isoforms metab-
olizing chloroquine.25 A recently published study reported 
an association between CYP2C8*2 and *3 and gametocyte-
mia and parasitemia low clearance rates in chloroquine/
primaquine-treated patients. Consequently, these alleles are 
related to increased toxicity caused by a reduced elimination 
rate.26 The role of polymorphisms in these genes should be 
further investigated concerning chloroquine metabolism. A 
higher toxicity in individuals with polymorphisms encoding 
inactive enzymes would be expected.
REMDESIVIR
Remdesivir, an antiviral drug, was developed to treat RNA-
based viruses that maintained global pandemic potential, 
such as Ebola virus and the Coronaviridae family viruses 
Middle East respiratory syndrome (MERS) and severe 
acute respiratory syndrome virus-1 (SARS-CoV-1). Antiviral 
activity was confirmed against SARS-CoV-1 and MERS 
zoonotic coronaviruses, as well as the circulating human 
coronaviruses HCoV-OC43 and HCoV-229E, which cause 
the common cold.27 In vitro and preclinical in vivo animal 
models supported the effectiveness of remdesivir against 
SARS-CoV-2.28,29 Several clinical trials are being performed 
to confirm its effectiveness and the clinical improvement of 
patients with COVID-19. Based on these initial findings, the 
FDA issued an Emergency Use Authorization for remdesivir 
in hospitalized patients. This drug was the first autho-
rized investigational therapeutic option for COVID-19.27 
Preliminary clinical trials demonstrated remdesivir effec-
tiveness for the treatment of COVID-1930 and its use was 
authorized for the treatment of the disease.31
Remdesivir is a nucleoside analog and acts as an RNA-
dependent RNA polymerase inhibitor, which is a protein 
complex used by the virus to replicate its genome. After 
the host metabolizes remdesivir into active nucleotide 
triphosphate, the metabolite competes with adenosine tri-
phosphate for incorporation into the RNA strand of the virus 
causing premature termination of its synthesis.32
To date, few data are available about the metabolism of 
remdesivir. The drug appears to be an in vitro substrate of 
CYP2C8, CYP2D6, and CYP3A4. Nevertheless, its in vivo 
metabolism seems to be dominated by hydrolase activity. 
Therefore, no possible drug-drug interactions are likely to 
occur with any CYP2C8, CYP2D6, and CYP3A4 inhibitors 
and inducers.33 In addition, poor metabolizers (PMs) for any 
of these enzymes are unlikely to be associated with a dif-
ferent clinical outcome. Congruently, according to current 
knowledge, no guideline recommends pharmacogenetic 
testing before remdesivir administration.
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Concerns about the possibility that inhibitors of the renin–
angiotensin–aldosterone system (RAAS) could predispose 
individuals to severe COVID-19 were raised.34 SARS-CoV-2 
enters pulmonary cells through the angiotensin converting 
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Nicotine CYP1A1 and CYP1A2 3
Fluvoxamine CYP2D6 1
Ruxolitinib CYP3A4 and CYP2C9 4
Baricitinib CYP3A4 and ABCB1 4
Anakinra IL-1 rs17651 3
Colchicine CYP2D6 3
Levels of evidence. 1: Biomarkers with clinical pharmacogenetic guidelines; 
2: Biomarkers with clinical pharmacogenetic guidelines applied to other 
drugs; 3: Candidate pharmacogenetic biomarkers as published in peer-
review journals without clinical pharmacogenetic guidelines; 4: Speculative 
biomarkers.
ABCB1, ATP binding cassette subfamily B member 1; ACE, angiotensin-
converting enzyme; ADD1, adducin 1 (alpha); COVID-19, coronavirus 
disease 2019; CYP, cytochrome P450; G6PD, glucose-6-phosphate dehy-
drogenase; IFNL3, interferon lambda 3; IL-1, interleukin-1; IL-6R, interleu-
kin-6 receptor; UGT1A1, UDP glucuronosyltransferase family 1 member A1.
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enzyme (ACE)2, which is expressed in the membrane of 
pulmonary cells. ACE2 and ACE counterbalance each other 
and provide a homeostatic regulation of angiotensin (Ang)
II.35 Renin mediates the transformation of angiotensinogen 
into Ang I, ACE converts Ang I to Ang II, and ACE2 converts 
Ang II to Ang 1–7. Ang II produces vasoconstriction and 
hypertension by interacting with angiotensin receptors 1R 
and 2R (AT1R, AT2R) and Ang 1–7 produces vasodilation by 
interacting with the Mas receptor. Finally, Ang II stimulates 
the release of aldosterone on the adrenal cortex, which 
regulates blood volume, blood pressure, and levels of Na+, 
K+, and H+.36–38 Three drug families block the RAAS system 
at different levels: inhibitors of the ACE, namely enalapril or 
lisinopril, antagonists of the AT1R receptor, namely losar-
tan or irbesartan, and antagonists of aldosterone, namely 
spironolactone. The use of any of these families controls 
blood pressure through the explained mechanisms and up-
regulates the expression of ACE2.39 As this enzyme is the 
entrance for the SARS-CoV-2 into the cell, the upregulation 
of ACE2 was related to a worse COVID-19 prognosis.40 The 
use of RAAS inhibitors in patients with COVID-19 seems not 
to have any clinically relevant effect.34 There is no evidence 
for a dose-dependent ACE2 upregulation. Therefore, it is 
unlikely that the use of higher doses of RAAS inhibitors 
will produce a clinical effect. Therefore, RAAS inhibitors 
ought not to be discontinued. Another reason that justi-
fies the use of these drugs in patients with COVID-19 and 
hypertension is that hypertension was related to a worse 
COVID-19 prognosis.41
There are some pharmacogenetic predictors of disposi-
tion and response of RAAS inhibitors. Their consideration 
for the management of COVID-19 would control the up-
regulation of ACE2. For instance, losartan is metabolized 
by CYP2C9,42 therefore, genotyping some of its polymor-
phisms may condition the clinical benefits of losartan. The 
most common reduced-function variants are CYP2C9*2 
(Arg144Cys), and CYP2C9*3 (Ile359Leu). Approximately 
two-third of the white population express the wild-type 
genotype (CYP2C9*1/*1), one-third express either the 
*1/*2 or *1/*3 genotype, and <  2.5% of individuals ex-
press the *2/*2, *2/*3, and *3/*3 genotypes.43 In patients 
with secondary kidney diseases, increased blood pressure 
was registered more frequently in *2 and *3 variant carriers 
compared with wild-type individuals.42 Although, to date, 
no pharmacogenetic guideline was published with thera-
peutic recommendations on losartan, CYP2C9 genotyping 
could be beneficial for dose adjustment. An impaired 
metabolism would cause toxicity problems due to the ac-
cumulation of the drug.
Other pharmacogenetic biomarkers, namely ATP Binding 
Cassette Subfamily B Member 1 (ABCB1) gene variants, 
could be useful predictors of losartan response.44 These 
gene encodes the P-glycoprotein (P-gp), an efflux transporter 
that mediates the movements of xenobiotics between differ-
ent body compartments.45 Consequently, it can modulate 
drug pharmacokinetics. The most relevant polymorphisms 
in ABCB1 are C3435T (rs1045642), G2677T/A (rs2032582) 
and C1236T (rs1128503).46 Regarding ACE inhibitors, ACE 
rs1799752 was related to variability in captopril,47 enalapril,48 
and lisinopril49 effectiveness. This polymorphism consists of 
a 50-nucleotide deletion (del). Patients with the del/del diplo-
type were related to a worse clinical outcome. Concerning 
aldosterone antagonists, the best pharmacogenetic predic-
tor for spironolactone effectiveness is rs4961, located in the 
alpha-adducin gene, which predicts drug response in com-
bination with furosemide.50 Carriers of the G allele exhibited 
a better response to therapy compared with T allele carriers. 
Furthermore, polymorphism of the ACE2 gene and the viral 
ACE2 receptor gene was related to variability in COVID-19 
prognosis.51 To date, there is no clear evidence on the con-
tribution of this polymorphism to the susceptibility to the 
disease. However, polymorphisms in the ACE2 and ACE 
genes were associated with hypertension (ACE2 rs4240157, 
rs4646155, rs4830542, rs2074192 rs233575, rs2158083, 
and rs21068809, ACE G8790A, and I/D).51 Due to the ap-
parent relationship between hypertension and COVID-19 
prognosis, it may be of interest to genotype patients for 
ACE2 polymorphisms. In the context of the use of RAAS 
inhibitors, the detection of mutations in one of the system 
mediators (ACE2) may be of particular relevance.
RIBAVIRIN
Ribavirin is an antiviral medication used to treat respira-
tory syncytial virus and hepatitis C virus (HCV) infections 
and some viral hemorrhagic fevers.52 Its mechanism of ac-
tion is well-described: first, it incorporates into replicating 
RNA, which stops chain elongation; second, it inhibits the 
de novo synthesis of GTP, required for viral RNA synthesis; 
and third, it enhances the response of interferon-stimulated 
genes, making cells more susceptible against exogenous 
interferon and increasing the endogenous production. 
Because it demonstrated in vitro activity against SARS-
CoV-2 virus, it was used in a variety of clinical settings for 
the management of COVID-19.53
The rs12979860 polymorphism in the interferon lambda 
3 (IFNL3 and IL28B) gene is the strongest baseline predic-
tor of response to ribavirin in patients with HCV genotype 
1 treated with interferons and ribavirin, according to the 
Clinical Pharmacogenetics Implementation Consortium 
(CPIC). Patients with the favorable response genotype 
(rs12979860  CC) have better response (higher sustained 
virologic response (SVR)) compared with those with unfavor-
able response genotype (rs12979860 CT or TT). Precisely, 
individuals with CC genotype have ~ 70% chance for SVR 
after 48 weeks of treatment. Contrastively, only 30% of in-
dividuals with unfavorable response genotype have SVR 
after 48  weeks of treatment.54 Additionally, the Dutch 
Pharmacogenetics Working Group (DPWG) found some ev-
idence for lower treatment response in HLA-B*44-negative 
patients. However, there are no dosing recommendations 
currently as ~ 90% of the population is HLA-B*44-negative.55 
In summary, IFNL3 genotyping may be a predictor of riba-
virin/peginterferon response in patients with COVID-19, but 
further research on this biomarker is warranted.
INTERFERONS
Interferons (IFNs) are cytokines, which are produced and 
released by host cells as an antiviral response to trigger 
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the immune system, therefore, to stimulate protective 
defenses. IFNs have several other functions: they acti-
vate natural killer cells and macrophages, and increase 
the expression of major histocompatibility antigens.56 
Consequently, they are used to treat viral infections, such 
as chronic HCV, hepatitis B, human papillomavirus infec-
tions, and Kaposi’s sarcoma caused by AIDS. Moreover, 
they are also used in hairy-cell leukemia, chronic my-
elogenous leukemia, metastatic renal-cell carcinomas, 
cutaneous melanoma, hemangiomas, and multiple scle-
rosis.57 IFNs are classified into three types, type I, II (alfa 
and beta interferons), and type III (gamma interferon), 
based on the structure of their receptors on the cell 
membrane surface. Pegylated interferon, usually called 
peginterferon, is a recombinant form of the standard in-
terferon. PEG stands for polyethylene glycol.58 Currently, 
only IFN beta-1b is being investigated as a possible 
treatment for COVID-19. Nevertheless, its efficacy was 
determined only in combination with lopinavir, ritonavir, 
and ribavirin.59
No pharmacogenetic recommendation is available for 
IFN beta-1b. However, the CPIC guideline recommends ge-
notyping the rs12979860 polymorphism in the IFNL3 gene 
during peginterferon alfa-2a and peginterferon alfa-2b ther-
apy of HCV in combination with ribavirin.54 Several other 
polymorphisms, such as rs8099917 and rs1188122, are 
being investigated in IFNL3 and IFNL4 genes associated to 
IFNs. However, no clinical recommendation is available for 
any other than rs12979860.
In addition, a recent study showed that homozygosity 
for the C allele of rs12252 in the IFITM3 gene is associated 
with more severe COVID-19 prognosis in an age-dependent 
manner.60 IFITM3 is a potent antiviral protein that enhances 
cellular resistance to a variety of pathogens, including in-
fluenza virus.61 Consequently, homozygous for the CC 
genotype of rs12252 may not have this protective effect 
against the serious symptoms of COVID-19.
LOPINAVIR AND RITONAVIR
Lopinavir and ritonavir are usually co-administered an-
tiretroviral drugs of the protease inhibitor class and 
used against HIV infections. The co-administration of 
lopinavir and ritonavir produces its antiviral effect by 
inhibiting the formation of infectious virions, thus prevent-
ing subsequent waves of cellular infection.62 Based on a 
recent study, it appears that these drugs are inhibitors 
of SARS-CoV-2 3CLpro protein, which is responsible for 
the cleavage of polyproteins into an RNA-dependent RNA 
polymerase and a helicase 1 during the replication pro-
cess.63 CYP3A4 is involved in their metabolism. Lopinavir 
and ritonavir are contraindicated with drugs that are highly 
metabolized by CYP3A enzymes or are potent CYP3A 
inducers, according to the FDA-approved label.64 The 
most studied no function CYP3A4 alleles are CYP3A4*6, 
CYP3A4*20, and CYP3A4*26. The CYP3A4*20 allele has 
a frequency of about 1.2% in white patients; with a fre-
quency that reaches up to 3.8% in specific regions.65 
CYP3A4*22, with the MAF of 5% in white patients, is a 
reduced function allele.66 Additionally, CYP3A4*2 and *3 
were identified as missense polymorphisms67 decreasing 
the function of the enzyme with a frequency of 1.1 and 
2.1% in white patients, respectively.68,69 Nevertheless, the 
exact role of these polymorphisms are currently unknown. 
These polymorphisms are unlikely to have a relevant ef-
fect, as ritonavir completely blocks CYP3A4, which is, in 
fact, prescribed with this intention in order to increase 
lopinavir exposure.
ATAZANAVIR AND RITONAVIR
Atazanavir is an inhibitor of the HIV protease, one of the viral 
molecules targeted in the clinical management of AIDS. It 
is typically co-administered with ritonavir and other anti-
viral drugs in highly active antiretroviral therapy.70 In vitro 
and ex silico investigations reported atazanavir to medi-
ate SARS-CoV-2 major protease inhibition.71,72 The CPIC 
dosing guideline on atazanavir and UDP glucuronosyl-
transferase family 1 member A1 (UGT1A1) gene classifies 
individuals according to UGT1A1 alleles into normal me-
tabolizers (NMs), intermediate metabolizers (IMs) and 
PMs. The PMs (i.e., carriers of two decreased function 
alleles) are more likely to develop jaundice, which may 
cause nonadherence, and alternative drugs should be 
considered. The risk of discontinuation is low or very low 
for individuals carrying one or zero decreased-function 
alleles (IMs and NMs).73 Table 2 shows some examples 
of genotype-phenotype inference. In conclusion, UGT1A1 
genotyping in atazanavir-treated patients with COVID-19 
could improve therapy tolerability.
STEROIDS
Previous epidemics of coronaviruses, such as SARS-
CoV-1 and MERS, demonstrated that the unregulated 
inflammatory response could eventually lead to an ag-
gression on the respiratory system.74 However, patients 
with severe COVID-19 undergo inflammatory-induced 
lung injuries, for what corticosteroids were indicated, 
namely hydrocortisone, prednisone, methylprednisolone, 
prednisolone, or dexamethasone.75 To date, no pharma-
cogenetic guideline was published on any corticosteroid 
and no pharmacogenetic recommendations can be ad-
dressed. However, ABCB1 polymorphism was related 
to variability in dexamethasone effectiveness, and to 
variability in methylprednisolone, prednisone, and pred-
nisolone tolerability, probably due to the variability on 
drug exposure.76–79 The ABCB1 gene encodes the P-gp, 
an efflux transporter responsible for the transport of 
xenobiotics across different body compartments; its poly-
morphism can cause loss of function on the transporter 
and relevant pharmacokinetic alterations.45,46 Apart from 
traditional corticosteroids, the sexual hormone proges-
terone was repurposed for the treatment of COVID-19 
(ClinicalTrials.gov: NCT04365127). It is metabolized by 
CYP3A4, CYP2C19, and CYP2C9 enzymes. However, 
only CYP2C19 phenotype seems relevant to significantly 
alter drug bioavailability.80 In patients with COVID-19, it 
could be of interest to closely observe CYP2C19 PMs 
(*2/*2 or *2/*3) for the risk of toxicity and to titrate dose to 
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reach clinical efficacy for CYP2C19 ultrarapid metaboliz-
ers (*17/*17).
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cy-
clooxygenase enzymes 1 or 2 (COX1 and 2) impeding the 
production of prostaglandins (involved in the process of in-
flammation) and thromboxane (modulating blood clotting). 
NSAIDs may be prescribed for the management of pain and 
fever. Controversy arose on the use of NSAIDs due to the 
possibility of a worse COVID-19 prognosis.81 However, the 
European Medicines Agency (EMA) declared that there is 
no evidence in this respect and that NSAIDs may be used 
for COVID-19 management.82
In March 2020, the CPIC published a pharmacogenetic 
guideline on NSAIDs.83 Specific therapeutic recommen-
dations are acknowledged for celecoxib, flurbiprofen, 
ibuprofen, lornoxicam, meloxicam, piroxicam, and tenoxi-
cam based on CYP2C9 phenotype. This phenotype is 
inferred from an activity score, which is obtained by the 
sum of two individual allele scores (Table 3). A functional 
allele is assigned a score of 1, whereas reduced-function 
(e.g., *2) and no-function (e.g., *3) alleles receive the score 
of 0.5 and 0, respectively. IMs or PMs may be overexposed 
to these drugs, that justifies dose reductions or changes in 
the prescription. For celecoxib, flurbiprofen, ibuprofen, and 
lornoxicam, CYP2C9 NMs and IMs with an activity score of 
1.5 are recommended to initiate therapy with the approved 
starting dose. For IMs with an activity score of 1.0, therapy 
should start with the lowest recommended dose and titrate 
to clinical effect. Finally, the clinical recommendation for 
PMs involves sharp dose reductions (initiating therapy with 
25–50% of the lowest recommended starting dose) or using 
alternative drugs (e.g., acetylsalicylic acid, metamizole, or 
naproxen). For meloxicam, piroxicam, and tenoxicam, the 
recommendations for CYP2C9 NMs and IMs with an activity 
score of 1.5 are similar to celecoxib, flurbiprofen, ibuprofen, 
or lornoxicam. For IMs with activity score of 1.0, meloxicam 
should be prescribed with 50% of the lowest starting dose 
or an alternative drug may be used; for PMs, an alternative 
drug should be used. For piroxicam and tenoxicam, IMs with 
an activity score of 1.0 and PMs should receive an alterna-
tive drug.
TOCILIZUMAB, SARILUMAB, AND SILTUXIMAB
A large number of T-lymphocytes and mononuclear 
macrophages are activated in patients suffering from 
COVID-19. Consequently, they induce cytokines, such as 
IL-6, which binds to the IL-6 receptor on the target cells, 
causing the cytokine storm and severe inflammatory re-
sponses, particularly in the lungs. Tocilizumab, sarilumab, 
and siltuximab are monoclonal antibodies that target IL-6 
receptor (tocilizumab and sarilumab) or IL-6 (siltuximab). 
Consequently, they inhibit IL-6 mediated signaling, mit-
igating the inflammatory response.84 Tocilizumab and 
sarilumab are used for the treatment of rheumatoid ar-
thritis,85,86 whereas siltuximab is used for the treatment of 
Multicentric Castleman’s disease, a lymphoproliferative 
disorder often associated to human herpes virus 8, 
which is more frequently seen in the presence of an HIV 
infection.87
To date, no pharmacogenetic testing is recommended for 
tocilizumab. Nevertheless, several studies were performed 
to investigate the association between genetic polymor-
phisms in IL6R gene and tocilizumab response. Patients with 
IL6R rs4329505 CC and CT genotypes may have decreased 
response to tocilizumab as compared with patients with TT 
genotype.88 Moreover, rs12083537 AA genotype was asso-
ciated with decreased response to tocilizumab and higher 
risk for asthma as compared with AG genotype.88 Finally, 
rs11265618 CC genotype was associated to increased 
response to tocilizumab as compared with CT and TT gen-
otypes.89 Polymorphisms in CD69, FCGR3A, and GALNT18 
genes were also associated with tocilizumab response. 
Table 2 UGT1A1 phenotype inference based on genotype information
UGT1A1
Normal metabolizers
*1/*1, *1/*36, *36/*36 2 reference function (*1/*1) and/or 
increased function allele (*36)
rs887829 C/C rs887829 C/C homozygosity
Intermediate metabolizers
*1/*28, *1/*37, *36/*28, *36/*37 1 reference function (*1) or 
increased function allele (*36) 
and 1 decreased function allele 
(*6, *28, *37)
rs887829 C/T (*1/*80) rs887829 C/T heterozygosity
Poor metabolizers
*28/*28, *28/*37, *37/*37, *6/*6 2 decreased function alleles  
(*6, *28, *37).
rs887829 T/T (*80/*80) rs887829 T/T homozygosity
Information obtained from Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guideline on atazanavir and UGT1A1.73
UGT1A1, UDP glucuronosyltransferase family 1 member A1.
Table 3 CYP2C9 phenotype inference based on genotype information
CYP2C9
Normal metabolizers
AS = 2.0 *1/*1 2 normal-function alleles
Intermediate metabolizers





AS = 1.0 *1/*3, *2/*2, *2/*5, 
*2/*8, *2/*11, *5/*5, 













AS = 0 *3/*3 2 no-function alleles
Information obtained from Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guideline on non-steroidal anti-inflammatory drugs and 
CYP2C9.83
AS, activity score; CYP2C9, cytochrome P450 2C9.
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Patients with the CD69 rs11052877 AA genotype may have 
an increased response to tocilizumab compared to patients 
with the AG and GG genotypes.90 In addition, patients with 
the FCGR3A rs396991 AA genotype may have an increased 
response to tocilizumab as compared with patients with the 
AC or CC genotypes.91 Finally, GALNT18 rs4910008 CC 
individuals may have increased response to tocilizumab 
compared with patients with the CT and TT genotypes.90 
However, these studies state that other genetic and clinical 
factors may affect the response to tocilizumab.
Concerning sarilumab, very little pharmacogenetic 
information is available. Similar to tocilizumab, it is metabo-
lized by catabolic pathways and not by CYP450 enzymes. 
Nevertheless, elevated levels of IL-6 decrease CYP3A4 ac-
tivity. Consequently, the use of these monoclonal antibodies 
enhance CYP3A4 activity and reduce CYP3A4 substrate ex-
posure, such as simvastatin.86 The same mechanism may 
occur with CYP2C9 and CYP2C19.92 Consequently, CYP3A4 
metabolizer status should be evaluated in patients receiving sa-
rilumab or tocilizumab with a CYP3A4 substrate. Furthermore, 
due to their same mechanism of action, the associations es-
tablished for tocilizumab could also affect sarilumab.
To the best of our knowledge, to date, only an Italian 
study—SISCO (siltuximab in serious COVID-19)—admin-
istered siltuximab for COVID-19 treatment. Twenty-one 
patients who developed acute respiratory distress syn-
drome received intravenous siltuximab. An improvement 
was experienced in the clinical condition of 33% of pa-
tients, 43% stabilized and the condition of 24% of patients 
worsened; among this group, 1 patient died, and 1 patient 
experienced a cerebrovascular event.93 Siltuximab is pre-
sumably degraded into small peptides and amino acids via 
catabolism.87 Nevertheless, similarly to sarilumab, it may in-
terfere with CYP450 activity. The FDA drug label states that 
siltuximab treatment can lead to the increased metabolism 
of CYP450 substrates, especially CYP3A4. This could be 
due to the fact that CYP450 enzymes are suppressed by cy-
tokines, such as IL-6 in case of infection and inflammation.94 
Consequently, drug levels should be checked and the dose 
of siltuximab should be adjusted if necessary.
SIROLIMUS
Sirolimus, also known as rapamycin, is a macrocyclic triene 
antibiotic with potent antifungal, antitumoral, and immuno-
suppressant activity. Its immunosuppressant activity is the 
consequence of very complex intracellular interactions; it 
interacts with immunophilins and blocks the transcriptional 
activation of several cytokine genes, impeding cytokine 
production, and inhibiting the activation of T and B cells by 
reducing their sensitivity to IL-2.95,96 It is mainly prescribed 
to prevent organ transplant rejection, especially kidney, and 
the graft-vs.-host disease. Sirolimus, in combination with 
dactinomycin, was repurposed for the treatment of COVID-
19 as synergistically targeted human coronavirus protein 
subnetwork.97 This drug is currently being investigated in 
phase I/II clinical trials (ClinicalTrials.gov: NCT04371640 
and NCT04341675). It is mainly metabolized by CYP3A4/5.98 
Most people are nonexpressers of CYP3A5 (i.e., carriers of 
the *3/*3 diplotype). However, some of them preserve the *1 
allele, therefore, express CYP3A5 and metabolize sirolimus 
to a greater extent than nonmetabolizers and show reduced 
sirolimus bioavailability. Consequently, CYP3A5 expressers 
(*1/*1 and *1/*3) were related to higher dose requirements 
compared with CYP3A5 nonexpressers (*3/*3).99 Although 
there is no pharmacogenetic guideline on sirolimus and 
CYP3A5, for the structurally related drug tacrolimus, a 
pharmacogenetic guideline was published in 2015.100 For 
CYP3A5 expressors, an initial dose of 1.5 to 2 times the 
standard one is recommended to reach therapeutic con-
centrations. Nevertheless, there is not enough evidence 
currently to apply these dose adjustments to everolimus.
NICOTINE
Smoking, along with its related conditions (e.g., cardiovas-
cular diseases and chronic obstructive pulmonary disease), 
are known to increase the risk for respiratory infection 
susceptibility and severity. Nevertheless, nicotine seems 
to have protective effects by enhancing the cholinergic 
anti-inflammatory pathway.101 Additionally, it is suspected 
that COVID-19 may be a disease of the nicotinic cholinergic 
system.101
Nicotine induces CYP1A1 and CYP1A2 enzymes in the 
lungs, which can activate carcinogens. The most com-
mon variants in CYP1A1 are *2A (rs4646903), and *2C 
(rs1048943), whose combination defines *2B. All three have 
uncertain functions. Moreover, CYP1A1*3 seems to have 
enhanced enzyme activity, although it is very rare in white 
people. Finally, CYP1A1*4, with 3% MAF in white people, 
was also related to greater enzyme catalytic efficiency.102 
Several studies reported increased risk for lung cancer in 
the presence of some of these variants, however, no clear 
conclusion was established to date.103,104 The three most 
common CYP1A2 variants are *1B (probably decreased 
function), *1C (decreased function), and *1F (confers higher 
inducibility).105 Decreased enzyme activity slows down 
elimination of xenobiotics and can result in increased drug 
concentrations and enhanced drug effects.106 Therefore, 
CYP1A1 and CYP1A2 selected polymorphisms could be 
genotyped in patients with COVID-19 when receiving nico-
tine therapy to evaluate their possible effects.
FLUVOXAMINE
Fluvoxamine is an antidepressant, which belongs to the se-
lective serotonin reuptake inhibitor class. The drug is used 
primarily for the treatment of obsessive–compulsive dis-
order, however, it is also used for depression and anxiety 
disorders, such as panic disorder, social anxiety disor-
der, and post-traumatic stress disorder.107 Although there 
is no recommendation of fluvoxamine for the treatment of 
COVID-19, a phase I clinical trial is being conducted cur-
rently in outpatients to test if serious complications, such 
as shortness of breath, can be prevented.108 It was shown 
previously that fluvoxamine reduced the inflammatory re-
sponse—a cytokine storm—during sepsis.109 The second 
phase of COVID-19 can involve a serious inflammatory re-
action,110 which may be prevented if fluvoxamine is used for 
treatment.
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The CPIC and DPWG Consensus Dosing Guideline rec-
ommends a 25–50% dose reduction for the starting dose 
of fluvoxamine, or the use of an alternative drug, which is 
not metabolized by CYP2D6 for CYP2D6 PMs (*3/*4, *4/*4, 
*5/*5, and *5/*6). The guideline does not recommend any 
dose adjustment for ultrarapid metabolizers, NMs, or IMs. 
Table 4 shows the inference of CYP2D6 phenotype based 
on genotypes.111
Moreover, the FDA-approved drug label states that pa-
tients with low CYP2D6 activity and those receiving other 
medications known to inhibit CYP2D6 should be moni-
tored.112 The Swiss drug label concurs with this fact; it 
states that the pharmacological properties and relative 
proportions of metabolites of fluvoxamine are altered in 
CYP2D6 PM.113 In addition, the DPWG evaluated the ther-
apeutic dose recommendation for fluvoxamine based on 
CYP2C19 genotypes. They concluded that no dose adjust-
ment is needed.114
RUXOLITINIB AND BARICITINIB
Ruxolitinib is used for the treatment of high-risk myelo-
fibrosis and polycythemia vera along with many other 
possible options, such as psoriasis and steroid-refractory 
acute graft-vs.-host disease. It is a Janus-associated ki-
nase (JAK 1/2) inhibitor. JAK1 and JAK2 play key roles in 
cellular responses during inflammation, growth, regula-
tion of metabolism, and gene transcription. Consequently, 
ruxolitinib might be effective against the consequences of 
elevated cytokine levels in patients with COVID-19. A recent 
study showed that adding ruxolitinib to standard-of-care 
(usually including remdesivir) treatment was not associ-
ated with clinical improvement in patients with COVID-19. 
Nevertheless, ruxolitinib recipients had faster clinical 
improvement compared with the control group who did not 
receive any treatment.115
The FDA ruxolitinib drug label does not contain pharma-
cogenetic information. Nevertheless, it states that ruxolitinib 
is metabolized by CYP3A4 and CYP2C9, and suggests 
dosing adjustments and more frequent monitoring of hema-
tology parameters if co-administered with strong CYP3A4 
inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), or 
dual inhibitors of CYP3A4 and CYP2C9 (e.g., fluconazole). 
However, the drug label also states that ruxolitinib and its 
M18 metabolite do not inhibit CYP1A2, CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, or CYP3A4, do not induce 
CYP1A2, CYP2B6, or CYP3A4, and do not inhibit the P-gp 
transport system at clinically relevant concentrations in 
vitro.116 More studies are needed in order to access accu-
rate pharmacogenetic information for ruxolitinib. However, 
the CYP3A4 and CYP2C9 PMs should be closely followed 
for the risk of drug accumulation and toxicity.
Baricitinib, similarly to tofacitinib, is a JAK 1/2 inhibitor. It 
is used for the treatment of rheumatoid arthritis in patients 
whose disease was not well controlled with tumor necrosis 
factor antagonists. Furthermore, it appears to have antivi-
ral activity by its affinity for AP2-associated protein AAK1, 
reducing SARS-CoV-2 endocytosis.117 In a recent clinical 
trial, in which patients with COVID-19 showing fever, cough, 
myalgia, fatigue, or pneumonia were included, baricitinib sig-
nificantly improved the clinical and laboratory parameters. 
None of the patients required intensive care unit support and 
most of them were discharged.118
The drug label states that baricitinib is a CYP3A4 sub-
strate in vitro. Nevertheless, in clinical pharmacology 
studies, ketoconazole, a CYP3A4 inhibitor, did not affect 
the pharmacokinetics of baricitinib. Moreover, fluconazole, 
a CYP3A, CYP2C9, and CYP2C19 inhibitor, and rifampicin, 







Duplicated normal function alleles in combination with 
(1) a decreased function allele other than CYP2D6*10 or 
(2) another normal function allele
Normal metabolizers
AS = 2.25 *1x2/*10, *2x2/*10 Duplicated normal function alleles in combination with CYP2D6*10
AS = 2.0 *1/*1, *1/*2 2 normal function alleles
AS = 1.5 *1/*41, *1/*9 A normal function allele plus a decreased function allele other than 
CYP2D6*10
AS = 1.25 *1/*10 CYP2D6*10 plus a normal function allele
Intermediate metabolizers
AS = 1.0 *41/*41, *1/*5 2 decreased function alleles other than CYP2D6*10
AS = 0.75 *9/*10, *10/*41 CYP2D6*10 plus another decreased function allele
AS = 0.5 *4/*41, *10/*10 CYP2D6*10/*10
AS = 0.25 *4/*10 CYP2D6*10 plus a no function allele
Poor metabolizers
AS = 0 *3/*4, *4/*4, *5/*5, *5/*6 2 no function alleles
Information obtained from Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group standardizing con-
sensus on CYP2D6 genotype to phenotype translation.111
AS, activity score; CYP2D6, cytochrome P450 2D6.
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a CYP3A inducer, did not alter baricitinib pharmacokinetics. 
In vitro studies suggest that baricitinib is a P-gp substrate, 
however, clinical studies concluded that P-gp inhibitors and 
substrates, such as cyclosporine and methotrexate, respec-
tively, did not affect its pharmacokinetics.119 Based on these 
data, more studies are needed to conclude useful pharma-
cogenetic information.
ANAKINRA
Anakinra is a recombinant form of human interleukin-1 re-
ceptor antagonist (IL-1RA), an endogenous key mediator that 
inhibits the IL-1 signaling pathway. IL-1 causes inflammation 
and hyperproliferative cutaneous disorders. Consequently, 
anakinra is prescribed for the management of inflamma-
tory120 or cutaneous121 diseases. Anakinra does not suffer 
CYP450 metabolism and undergoes extensive kidney elim-
ination. It was repurposed for COVID-19 treatment as IL-1 
is one of the cytokines involved in the development of the 
cytokine storm.122 Polymorphisms in genes related with 
pharmacokinetics seem irrelevant. However, the IL-1α 
G4845T (rs17651) T allele was significantly related to re-
sponsiveness to anakinra; the variant was reported to alter 
IL-1α production.123
COLCHICINE
Colchicine is an alkaloid indicated for several disorders, 
including, but not limited to: familial Mediterranean fever, 
Bechet’s disease, pericarditis, coronary artery disease, and 
inflammatory and fibrotic diseases. The mechanism of ac-
tion is not fully understood. Colchicine inhibits neutrophil 
chemotaxis, adhesion, and mobilization; inhibits NACHT-
LRRPYD-containing protein 3 inflammasomes; inhibits IL-1β 
processing and release.124 It was repurposed for COVID-19 
treatment to direct its anti-inflammatory properties against 
the cytokine storm (ClinicalTrial.gov: NCT04326790, 
NCT04322682, and NCT04322565).125 Although CYP3A4 is 
involved in colchicine metabolism and it is a substrate of the 
P-gp, polymorphisms in the ABCB1 gene had no effect on 
the response to colchicine.126 Contrastively, the no-function 
and decreased-function CYP2D6 alleles *4 and *10 were 
significantly related to a worse response to colchicine.127
CONCLUSIONS
More than half a year after the outbreak of the SARS-CoV-2 
virus worldwide, only remdesivir was proven to be effective 
against COVID-19. Despite immense efforts by the scien-
tific, pharmaceutical, and medical communities, more drugs 
effective in the management of the disease are required. 
Therefore, until herd immunity is achieved, a vaccine is mar-
keted, or the virus is eradicated, the risk of new outbreaks is 
high. In the absence of effective drugs, the off-label use of 
drugs will continue. In this review, we provide a range of drugs 
for which therapeutic actions are available based on pharma-
cogenetics. As long as these drugs continue to be used, they 
must be used as safely as possible. In the coming months, 
other drugs may be used to treat the disease with available 
pharmacogenetic guidelines. It is the responsibility of the 
specialists in pharmacogenetics to draft and promote this 
type of review, providing easily accessible information to help 
improve the clinical management of patients with COVID-19. 
Nevertheless, the level of evidence of many of the biomark-
ers described here is low. Consequently, it is necessary to 
perform more in-depth research on very important pharma-
cogenes to elaborate pharmacogenetic clinical guidelines. 
The implementation of pharmacogenetics in clinical settings 
is increasing as it leads to more efficient and cost-effective 
treatments. Currently, in times of a global healthcare crisis, 
these therapeutic improvements become crucial.
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